Back

Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis uncovered: from clues to cutting-edge care Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Marco Merlo

United Hospitals of Trieste University Hospital, Trieste (Italy)

2 More presentations in this session

Presentation thumbnail
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study
Doctor C. Fumagalli (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis uncovered: from clues to cutting-edge care
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
thumbnail
Congress Presentation
Evolving the understanding of TTR's role in health and disease​

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources